AVGO
Broadcom Inc.
AVGO's fundamentals are strong and it looks cheap: trading at 46x earnings, in line with its usual 49x, but only 19x next year's expected earnings.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AVGO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AVGO's revenue, profitability, cash flow and balance sheet are all currently strong.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AVGO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $364 | — |
| Cheap | 27x | $211 | -42% |
| Current | 46x | $364 | — |
| Fair | 49x | $384 | +5.3% |
| Expensive | 86x | $671 | +84% |
Historical ranges are pointers, not guarantees.
AVGO's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AVGO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Broad | |
| Moderate |
AVGO has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AVGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.23 | +145% |
| Q3 2026 | $7.84 | +100% |
| Q2 2026 | $6.01 | +125% |
| Q1 2026 | $5.13 | +145% |
| Q4 2025 | $4.77 | +288% |
| Q3 2025 | $3.92 | +241% |
| Q2 2025 | $2.67 | +15% |
| Q1 2025 | $2.09 | -23% |
| Q4 2024 | $1.23 | -63% |
AVGO has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AVGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $29.6B | +86% |
| Q2 2026 | $22.2B | +48% |
| Q1 2026 | $19.3B | +29% |
| Q4 2025 | $18B | +28% |
| Q3 2025 | $16B | +22% |
| Q2 2025 | $15B | +20% |
| Q1 2025 | $14.9B | +25% |
| Q4 2024 | $14.1B | +51% |
AVGO's revenue has grown year over year every quarter since late 2020: $29.6B last quarter, up 86% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 54% | +17 points |
| Q2 2026 | 49% | +9.8 points |
| Q1 2026 | 44% | +2.4 points |
| Q4 2025 | 42% | +8.8 points |
| Q3 2025 | 37% | +7.9 points |
| Q2 2025 | 39% | +15 points |
| Q1 2025 | 42% | +25 points |
| Q4 2024 | 33% | -13 points |
AVGO has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AVGO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AVGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.7B | +95% |
| Q2 2026 | $10.3B | +60% |
| Q1 2026 | $8B | +33% |
| Q4 2025 | $7.5B | +36% |
| Q3 2025 | $7B | +47% |
| Q2 2025 | $6.4B | +44% |
| Q1 2025 | $6B | +28% |
| Q4 2024 | $5.5B | +16% |
AVGO has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
AVGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +11M shares |
| 1 year | +0.6% | +27M shares |
| 3 years | +14% | +617M shares |
| 5 years | +14% | +597M shares |
| Available history | +17% | +697M shares |
AVGO has 4.9B diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $600M |
| Q1 2026 | $7.9B |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | — |
| Q4 2024 | — |
AVGO spent $8.4B buying back its own shares over the past year, about three times what it spent the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AVGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AVGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.3x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 4.1x | High |
AVGO's net debt is less than a year of its operating earnings (EBITDA), down from 2.3 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AVGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 20.3 | Neutral |
AVGO's weekly RSI is 51 (neutral) and its Stochastic is 20 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AVGO PE vs Technology Sector
| Metric | AVGO | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 28x | 67% above |
| PE % | 47 | 35 | 12 pts above |
AVGO is trading at 46x earnings, a 67% premium to the Technology sector's median of 28x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AVGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $338.0 | 7.8% above |
| 20 week MA | $362.1 | 0.6% above |
| 50 week MA | $363.0 | 0.4% above |
| 100 week MA | $313.8 | 16% above |
| 200 week MA | $214.3 | 70% above |
AVGO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AVGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.7 | $43.2 | +36% |
| 2021 | $43.2 | $66.5 | +54% |
| 2022 | $66.5 | $55.2 | -17% |
| 2023 | $55.2 | $111.6 | +102% |
| 2024 | $111.6 | $241.8 | +117% |
| 2025 | $241.8 | $352.1 | +46% |
| 2026 YTD | $352.1 | $364.4 | +3.5% |
AVGO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.